Our Science
Durable tumor control has to be designed across the whole product.
A cell therapy must be ready in time, reach the disease, recognize a changing tumor, and resist the pressures that follow.
- Ready
- Reach
- Recognize
- Resist
Why Resist
The tumor ecosystem sends overlapping signals that shut CAR-T cells down.
Across solid tumors, tumor cells, immune cells, stroma, and local chemistry create overlapping routes to T-cell dysfunction. Those pressures can persist after CAR-T cells reach and recognize the tumor, acting together to erode function.
Blocking one route can leave the others active.
Our approach
Build resistance into the cell.
We use multiplex base editing to knock out selected receptors in the same CAR-T cell. The combination is designed to interrupt several routes into dysfunction while preserving CAR-driven tumor recognition.
The signals remain. Selected routes into dysfunction are disconnected.
Across solid tumors
Built on what solid tumors share.Tuned for where they differ.
Solid tumors draw on many of the same suppressive pathways, but the dominant pressures differ by disease. KiraLOGIC prioritizes combinations from a shared resistance repertoire, so the engineering foundation and what we learn can carry forward while each product is shaped by its disease context.
With support from disease foundations and collaborators, ongoing preclinical studies are evaluating this approach in diffuse midline glioma, including DIPG, and dedifferentiated liposarcoma (DDLPS).
